scholarly journals Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Naim Shehadeh ◽  
Itamar Raz ◽  
Afif Nakhleh
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Combination Therapy ◽  
Diabetes Treatment ◽  
Treatment Paradigm ◽  
Type 2 Diabetes Treatment ◽  
Early Combination Therapy ◽  
Cardiovascular Benefit

scholarly journals Early Combination Therapy for Type 2 Diabetes: Potentiation of Hypoglycemic Effects or Pathogenetic Approach

2020 ◽  
Vol 16 (25) ◽  
pp. 50-54
Author(s):  
V.V. Fadeev Fadeev ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Metabolic Disorders ◽  
Diabetes Treatment ◽  
Complex Effect ◽  
Type 2 Diabetes Treatment ◽  
Positive Effect ◽  
Early Combination Therapy

The article is devoted to the problem of type 2 diabetes treatment in modern conditions. Complex effect is being considered in the context of complex and ambiguous ideas about the pathogenesis and nature of the disease, according to which hyperglycemia is only one of many manifestations of metabolic disorders that develop in such patients. The author presents his own view on the pathogenetic approach to the treatment of newly identified type 2 diabetes mellitus – the appointment of several drugs with different hypoglycemic mechanisms. The preference for fixed combinations with the proven positive effect on cardiovascular risk is being justified

scholarly journals Carbohydrate digestive enzymes are inhibited by Poincianella pluviosa stem bark extract: relevance on type 2 diabetes treatment

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Camila Gabriel Kato-Schwartz ◽  
Anacharis Babeto de Sá-Nakanishi ◽  
Ana Carolina Guidi ◽  
Geferson de Almeida Gonçalves ◽  
Fernanda Giacomini Bueno ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Digestive Enzymes ◽  
Stem Bark ◽  
Bark Extract ◽  
Diabetes Treatment ◽  
Type 2 Diabetes Treatment ◽  
Stem Bark Extract

scholarly journals Type 2 Diabetes Mellitus. From the start – combination therapy

2018 ◽  
Vol 21 (5) ◽  
pp. 386-394 ◽  
Author(s):  
Francesco Indovina ◽  
Pierpaolo Falcetta ◽  
Stefano Del Prato
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Diabetes Diagnosis ◽  
Good Glycemic Control ◽  
Chronic Hyperglycemia ◽  
Increased Risk ◽  
History Of ◽  
First Time ◽  
Early Combination Therapy

Modern treatment of T2DM requires a shift in paradigm with appropriate intensification of therapy from the very first time of diabetes diagnosis. This is supported by data showing how even a moderate delay in achieving good glycemic control can translate into a later increased risk of developing diabetic complications. The recognition of the complexity of the pathogenesis of T2DM leads to the appreciation of the importance of attacking the disease from different angles, i.e. simultaneous tackling of multiple mechanisms contributing to hyperglycemia. From the turn of century a growing number of new anti-hyperglycemic agents have been made available. As compared to the older ones, these new medicines have a more targeted mechanism of action as they act at the level of the specific pathophysiologic disturbances accounting the development and progression of hyperglycemia. Because of that drugs can be use in combination taking advantage of their complementary mechanisms of action and synergistic. If introduced earlier in the natural history of the disease combination therapy may contribute avoiding undesirable exposure to even mild chronic hyperglycemia and provide early benefits. With respect to that in this review we will discuss advantages, disadvantages and still unanswered questions related to the use of early combination therapy in type 2 diabetes.

scholarly journals Type 2 Diabetes Treatment and Drug Development Study

2018 ◽  
Vol 8 (1) ◽  
pp. 22-33 ◽  
Author(s):  
Da-Yong Lu ◽  
Jin-Yu Che ◽  
Nagendra Sastry Yarla ◽  
Hong-Ying Wu ◽  
Ting-Ren Lu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Drug Targets ◽  
Medical Knowledge ◽  
Modern Medicine ◽  
Diabetes Treatment ◽  
Candidate Drug ◽  
The Future ◽  
Type 2 Diabetes Treatment ◽  
And Personalized Medicine

The causality and etio-pathologic risks for patients with Type 2 Diabetes (T2DM) are important areas in modern medicine. Disease complications are largely unpredictable in patients with T2DM. In the future, we welcome therapeutics of both cutting-edge and traditional for anti-diabetic treatments and management with higher efficiency and less cost. Expanding medical knowledge, behavior/life-style notification in healthcare, modern genetic/bioinformatics diagnostic promotion, clinical developments (Traditional Chinese Medicine and personalized medicine) and new drug developments - including candidate drug targets should be implemented in the future. These efforts might be useful avenues for updating anti-diabetic therapeutics globally. This article aims at introducing this information for T2DM treatment boosts.

Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment

2019 ◽  
Vol 27 (2) ◽  
pp. 394-409 ◽  
Author(s):  
Shoichi Kuroda ◽  
Yohei Kobashi ◽  
Takahiro Oi ◽  
Kenichi Kawabe ◽  
Fumiyasu Shiozawa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Treatment ◽  
Sodium Dependent ◽  
Type 2 Diabetes Treatment
Sign in / Sign up

Export Citation Format

Share Document